ClinicalTrials.gg
CompletedNCT04124965Updated Aug 20, 2026Results posted

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

A Phase 3 interventional study of Rozanolixizumab in Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL. Completed at 43 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing rozanolixizumab in Myasthenia Gravis — 2 open to participants now, 4 under way, 3 of them phase 3. rozanolixizumab · Myasthenia Gravis.

Enrollment
5th of 10
71 · median 67
Started
2019
with 1 other
Phase 3
7 of 10
2 open now
Registered
3rd of 10
by date
Lead sponsor
9 of 10
UCB Biopharma SRL

Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, this one is the 5th largest by enrollment, is one of 2 that started in 2019, is one of 7 in phase 3, and was the 3rd registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

2 of the 10 studies testing rozanolixizumab in Myasthenia Gravis are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rozanolixizumab

rozanolixizumab: first FDA approval 2023 (RYSTIGGO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing rozanolixizumab in Myasthenia Gravis, or all of them as a file.
02

Study summary

The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • UCB7665
  • generalized myasthenia gravis
  • rozanolixizumab
  • gMG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant was eligible for MG0003 [NCT03971422] or MGC003 at the time of enrollment into either study and the participant either completed the observation Period of MG0003 or MGC003 or required rescue therapy during the Observation Period of the lead-in studies
  • Body weight ≥35 kg at Visit 1
  • Study participants may be male or female

Exclusion criteria

Exclusion Criteria:

  • Evidence of active or latent tuberculosis (TB) as documented by medical history and examination, if applicable, chest X-rays (posterior anterior and lateral), and TB testing by a positive (not indeterminate) QuantiFERON®-TB Gold Plus
  • Participant has received a within 8 weeks prior to the Baseline visit; or intends to have a live vaccination during the course of the study or within 8 weeks following the final dose of study medication
  • Study participant has experienced reaction after exposure to other anti-neonatal Fc receptor (FcRn) drugs - Study participant with severe (defined as Grade 3 on the myasthenia gravis-activates of daily living (MG-ADL) scale) weakness affecting oropharyngeal or respiratory muscles, or who has myasthenic crisis or impending crisis
  • Participant has any laboratory abnormality that, in the opinion of the Investigator, is , has not resolved at randomization, and could jeopardize or compromise the study participant's ability to participate in this study
  • Study participant met any mandatory withdrawal or mandatory study drug discontinuation criteria MG0003 [NCT03971422] or MGC003, or discontinued study medication in either study, with the exception of discontinuation due to a need for rescue treatment
  • Study participant is not considered capable of adhering to the protocol visit schedule, or medication intake according to the judgment of the Investigator
  • Study participant has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or had suicidal ideation since the last visit in MG0003 as indicated by a positive response (Yes) to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Rozanolixizumab dosage regimen 1

    Study participants randomized to dosage regimen 1 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.

    Drug: Rozanolixizumab

  • Experimental
    Rozanolixizumab dosage regimen 2

    Study participants randomized to dosage regimen 2 will receive assigned dosage of rozanolixizumab at pre-specified time points during the Treatment Period. The dose regimen may be switched based on investigator discretion.

    Drug: Rozanolixizumab

Interventions

  • Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.

    Also known as: UCB7665

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    A TEAE is defined as an AE starting on or after the time of first administration of investigational medicinal product (IMP) or any unresolved event already present before the first administration of IMP that worsened in intensity following exposure to IMP, up to 8 weeks after the last dose of IMP in study participants who discontinued the study or IMP.

    Time frame: From Baseline until End of Study (up to Week 60)

  2. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of Study Medication

    A TEAE is defined as an AE starting on or after the time of first administration of IMP or any unresolved event already present before the first administration of IMP that worsened in intensity following exposure to IMP, up to 8 weeks after the last dose of IMP in study participants who discontinued the study or IMP.

    Time frame: From Baseline until End of Study (up to Week 60)

Secondary outcomes

  1. Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods

    The Myasthenia Gravis Activities of Daily Living (MG-ADL) is an 8-item patient-reported outcome (PRO) instrument developed on the basis of the Quantitative Myasthenia Gravis (QMG). The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0 represents no symptoms or impaired performance and 3 represents the most severe symptoms or impaired performance. The total score ranges from 0 to 24, with a higher score indicating more disability. A positive change indicates worsening and a negative change indicates improvement.

    Time frame: Baseline, Weeks 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 52 and 60

  2. Change From Baseline in Myasthenia Gravis-Composite (MG-C) Total Score at Each Scheduled Assessment During Treatment and Observation Periods

    MG-C scale is a validated assessment and scale tests 10 items with individual items being weighted differently. The items included ptosis/upward gaze (range: 0 \[\>45 second\] - 3 \[Immediate\]), double vision on lateral gaze (range: 0 \[\>45 second\] - 4 \[Immediate\]), eye closure (range: 0 \[Normal\] - 2 \[severe weakness\]), talking (range: 0 \[Normal\] - 6 \[difficult to understand speech\]), chewing (range: 0 \[Normal\] - 6 \[gastric tube\]), swallowing (range: 0 \[Normal\] - 6 \[gastric tube\]), breathing (range: 0 \[Normal\] - 9 \[ventilator dependence\]), neck flexion (range: 0 \[Normal\] - 4 \[severe weakness\]), shoulder abduction (range: 0 \[Normal\] - 5 \[severe weakness\]) and hip flexion (range: 0 \[Normal\] - 5 \[severe weakness\]), lower scores= lower disease activity. Total MG-C score was obtained by summing responses to each individual item and score ranges from 0 to 50, with lower scores indicating lower disease activity. A positive change indicates worsening and a negative change indicates improvement.

    Time frame: Baseline, Weeks 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 52 and 60

  3. Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Each Scheduled Assessment During Treatment and Observation Periods

    The QMG is a validated assessment and the scale tested 13 items, including ocular and facial involvement, swallowing, speech, limb strength, and forced vital capacity. The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3) and the score ranges from 0 to 39, with lower scores indicating lower disease activity. A positive change indicates worsening and a negative change indicates improvement.

    Time frame: Baseline, Weeks 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 52 and 60

  4. Percentage of Participants Using Rescue Medication (Intravenous Infusion of Immunoglobulin G (IVIg) or Plasma Exchange (PEX))

    Rescue therapy consisted of IVIg or PEX. Study participants who experienced disease worsening (eg, an increase of 2 points on the MG-ADL or 3 points on the QMG scale between 2 consecutive visits) may be considered for rescue therapy at the discretion of the Investigator.

    Time frame: From Baseline until End of Study (up to Week 60)

07

Results

Posted Aug 21, 2023

Participant flow

The study started to enroll study participants in Oct 2019 and concluded in Sep 2021.

Participant flow — Overall Study
MilestoneRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Started3536
Safety set3535
Completed53
Not completed3033
Withdrew: Adverse event, non-fatal31
Withdrew: Withdrawal by subject11
Withdrew: Rolled over to mg0007 study2528
Withdrew: Pregnancy10
Withdrew: Sponsor and participant decision01
Withdrew: Personal surgery01
Withdrew: Physician decision01

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

A TEAE is defined as an AE starting on or after the time of first administration of investigational medicinal product (IMP) or any unresolved event already present before the first administration of IMP that worsened in intensity following exposure to IMP, up to 8 weeks after the last dose of IMP in study participants who discontinued the study or IMP.

Time frame:
From Baseline until End of Study (up to Week 60)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)76.078.6
PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of Study Medication

A TEAE is defined as an AE starting on or after the time of first administration of IMP or any unresolved event already present before the first administration of IMP that worsened in intensity following exposure to IMP, up to 8 weeks after the last dose of IMP in study participants who discontinued the study or IMP.

Time frame:
From Baseline until End of Study (up to Week 60)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of Study Medication
percentage of participantsRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of Study Medication6.00
SecondaryChange From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods

The Myasthenia Gravis Activities of Daily Living (MG-ADL) is an 8-item patient-reported outcome (PRO) instrument developed on the basis of the Quantitative Myasthenia Gravis (QMG). The MG-ADL targeted symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The total MG-ADL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3), where 0 represents no symptoms or impaired performance and 3 represents the most severe symptoms or impaired performance. The total score ranges from 0 to 24, with a higher score indicating more disability. A positive change indicates worsening and a negative change indicates improvement.

Time frame:
Baseline, Weeks 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 52 and 60
Reported as:
Mean · units on a scale
Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Each Scheduled Assessment During Treatment and Observation Periods
units on a scaleRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Week 5-2.7 ± 3.3-3.2 ± 3.8
Week 7-2.7 ± 3.8-3.7 ± 3.4
Week 9-2.8 ± 3.4-3.4 ± 3.7
Week 13-3.1 ± 3.4-3.9 ± 4.0
Week 17-2.8 ± 3.3-4.0 ± 3.9
Week 21-3.0 ± 3.4-4.1 ± 4.3
Week 25-2.7 ± 3.0-3.7 ± 4.7
Week 29-2.8 ± 2.1-3.6 ± 4.3
Week 33-3.0 ± 2.8-3.5 ± 4.5
Week 37-3.9 ± 2.5-3.6 ± 3.6
Week 41-2.8 ± 2.1-1.8 ± 1.0
Week 45-3.8 ± 2.4-2.1 ± 1.1
Week 49-2.4 ± 1.1-0.5 ± 3.7
Week 52-2.6 ± 1.3-2.0 ± NA
Week 60-0.3 ± 2.1-1.3 ± 3.9
SecondaryChange From Baseline in Myasthenia Gravis-Composite (MG-C) Total Score at Each Scheduled Assessment During Treatment and Observation Periods

MG-C scale is a validated assessment and scale tests 10 items with individual items being weighted differently. The items included ptosis/upward gaze (range: 0 \[\>45 second\] - 3 \[Immediate\]), double vision on lateral gaze (range: 0 \[\>45 second\] - 4 \[Immediate\]), eye closure (range: 0 \[Normal\] - 2 \[severe weakness\]), talking (range: 0 \[Normal\] - 6 \[difficult to understand speech\]), chewing (range: 0 \[Normal\] - 6 \[gastric tube\]), swallowing (range: 0 \[Normal\] - 6 \[gastric tube\]), breathing (range: 0 \[Normal\] - 9 \[ventilator dependence\]), neck flexion (range: 0 \[Normal\] - 4 \[severe weakness\]), shoulder abduction (range: 0 \[Normal\] - 5 \[severe weakness\]) and hip flexion (range: 0 \[Normal\] - 5 \[severe weakness\]), lower scores= lower disease activity. Total MG-C score was obtained by summing responses to each individual item and score ranges from 0 to 50, with lower scores indicating lower disease activity. A positive change indicates worsening and a negative change indicates improvement.

Time frame:
Baseline, Weeks 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 52 and 60
Reported as:
Mean · units on a scale
Change From Baseline in Myasthenia Gravis-Composite (MG-C) Total Score at Each Scheduled Assessment During Treatment and Observation Periods
units on a scaleRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Week 5-4.7 ± 5.5-5.5 ± 7.3
Week 7-5.0 ± 5.7-7.1 ± 7.4
Week 9-5.0 ± 5.3-6.0 ± 7.4
Week 13-4.8 ± 5.5-7.0 ± 7.8
Week 17-4.4 ± 5.7-5.5 ± 8.6
Week 21-5.3 ± 6.9-7.3 ± 8.1
Week 25-6.1 ± 5.8-8.8 ± 7.7
Week 29-5.1 ± 5.5-9.1 ± 9.2
Week 33-4.6 ± 5.1-8.4 ± 8.6
Week 37-6.3 ± 6.8-8.6 ± 6.9
Week 41-6.0 ± 7.1-6.5 ± 5.8
Week 45-4.0 ± 6.2-5.3 ± 4.9
Week 49-1.4 ± 3.8-0.8 ± 9.2
Week 52-3.8 ± 3.1NA ± NA
Week 601.7 ± 3.7-2.3 ± 8.5
SecondaryChange From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Each Scheduled Assessment During Treatment and Observation Periods

The QMG is a validated assessment and the scale tested 13 items, including ocular and facial involvement, swallowing, speech, limb strength, and forced vital capacity. The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3) and the score ranges from 0 to 39, with lower scores indicating lower disease activity. A positive change indicates worsening and a negative change indicates improvement.

Time frame:
Baseline, Weeks 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 52 and 60
Reported as:
Mean · units on a scale
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Each Scheduled Assessment During Treatment and Observation Periods
units on a scaleRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Week 5-2.9 ± 4.7-4.5 ± 4.4
Week 7-3.3 ± 4.4-5.2 ± 4.3
Week 9-3.3 ± 3.8-4.7 ± 4.3
Week 13-2.6 ± 4.2-5.5 ± 4.4
Week 17-3.1 ± 4.9-4.2 ± 4.4
Week 21-4.0 ± 4.7-5.1 ± 4.9
Week 25-5.1 ± 4.6-5.7 ± 5.5
Week 29-5.4 ± 3.6-5.5 ± 6.3
Week 33-4.9 ± 4.8-6.2 ± 5.7
Week 37-5.3 ± 3.9-6.8 ± 5.9
Week 41-5.7 ± 4.3-4.0 ± 3.1
Week 45-5.3 ± 2.8-4.0 ± 3.5
Week 49-3.8 ± 0.8-1.8 ± 1.8
Week 52-4.6 ± 2.9NA ± NA
Week 60-0.9 ± 2.4-1.8 ± 5.1
SecondaryPercentage of Participants Using Rescue Medication (Intravenous Infusion of Immunoglobulin G (IVIg) or Plasma Exchange (PEX))

Rescue therapy consisted of IVIg or PEX. Study participants who experienced disease worsening (eg, an increase of 2 points on the MG-ADL or 3 points on the QMG scale between 2 consecutive visits) may be considered for rescue therapy at the discretion of the Investigator.

Time frame:
From Baseline until End of Study (up to Week 60)
Reported as:
Number · percentage of participants
Percentage of Participants Using Rescue Medication (Intravenous Infusion of Immunoglobulin G (IVIg) or Plasma Exchange (PEX))
percentage of participantsRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Percentage of Participants Using Rescue Medication (Intravenous Infusion of Immunoglobulin G (IVIg) or Plasma Exchange (PEX))11.40

Adverse events

Collected over From Baseline until End of Study (up to Week 60). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rozanolixizumab ~7 mg/kg0/50 (0%)7/50 (14%)27/50 (54%)
Rozanolixizumab ~10 mg/kg0/42 (0%)2/42 (4.8%)25/42 (59.5%)
Most frequent serious events
Most frequent serious events
EventRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
Myasthenia gravisNervous system disorders3/501/42
PericarditisCardiac disorders0/501/42
Cardiac failure congestiveCardiac disorders1/500/42
Retinal detachmentEye disorders1/500/42
Biopsy kidney abnormalInvestigations1/500/42
Muscular weaknessMusculoskeletal and connective tissue disorders1/500/42
Most frequent other events
Showing 10 of 13
Most frequent other events
EventRozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kg
HeadacheNervous system disorders15/5012/42
DiarrhoeaGastrointestinal disorders6/507/42
Blood immunoglobulin G decreasedInvestigations6/505/42
NauseaGastrointestinal disorders4/505/42
Urinary tract infectionInfections and infestations5/502/42
VomitingGastrointestinal disorders0/504/42
NasopharyngitisInfections and infestations2/504/42
RashSkin and subcutaneous tissue disorders1/504/42
PyrexiaGeneral disorders4/503/42
Back painMusculoskeletal and connective tissue disorders2/503/42

Baseline characteristics

Baseline Characteristics refer to the Randomized Set (RS) which consisted of all study participants who were randomized, using the treatment assigned instead of the actual treatment received.

Age, Categorical
Age, Categorical(Participants)Rozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
<=18 years000
Between 18 and 65 years292655
>=65 years61016
Age, Continuous
Age, Continuous(years)Rozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
Mean50.6 ± 14.253.7 ± 17.252.2 ± 15.8
Sex: Female, Male
Sex: Female, Male(Participants)Rozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
Female191938
Male161733
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
Asian448
Black235
White171936
Missing121022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rozanolixizumab ~7 mg/kgRozanolixizumab ~10 mg/kgTotal
Hispanic or Latino426
Not Hispanic or Latino192544
Missing12921
08

Study locations

43 sites
  • Mg0004 50081
    Phoenix, Arizona 85013-4409, United States
  • Mg0004 50072
    Los Angeles, California 90033, United States
  • Mg0004 50088
    Washington D.C., District of Columbia 20037, United States
  • Mg0004 50120
    Miami, Florida 33144, United States
  • Mg0004 50073
    Tampa, Florida 33612, United States
  • Mg0004 50114
    Indianapolis, Indiana 46202, United States
  • Mg0004 50121
    Lexington, Kentucky 40536, United States
  • Mg0004 50077
    New York, New York 10021, United States
  • Mg0004 50090
    Winston-Salem, North Carolina 27157, United States
  • Mg0004 50096
    Philadelphia, Pennsylvania 19104, United States
  • Mg0004 50066
    Montreal, Canada
  • Mg0004 50070
    Québec, Canada
  • Mg0004 50069
    Toronto, Canada
  • Mg0004 40125
    Ostrava-Poruba, Czechia
  • Mg0004 40124
    Prague, Czechia
  • Mg0004 40128
    Aalborg, Denmark
  • Mg0004 40129
    Bordeaux, France
  • Mg0004 40132
    Nice, France
  • Mg0004 40133
    Paris, France
  • Mg0004 40131
    Strasbourg, France
  • Mg0004 40140
    Göttingen, Germany
  • Mg0004 40078
    Leipzig, Germany
  • Mg0004 40177
    Münster, Germany
  • Mg0004 40144
    Milan, Italy
  • Mg0004 40146
    Pavia, Italy
  • Mg0004 40148
    Roma, Italy
  • Mg0004 40150
    Roma, Italy
  • Mg0004 20078
    Hanamaki Shi, Japan
  • Mg0004 20079
    Hiroshima, Japan
  • Mg0004 20077
    Miyagi, Japan
  • Mg0004 20076
    Shinjuku-Ku, Japan
  • Mg0004 20032
    Suita, Japan
  • Mg0004 40155
    Gdansk, Poland
  • Mg0004 40154
    Lodz, Poland
  • Mg0004 40151
    Lublin, Poland
  • Mg0004 20027
    Moscow, Russia
  • Mg0004 20001
    Saint Petersburg, Russia
  • Mg0004 20028
    Saint Petersburg, Russia
  • Mg0004 20055
    Saint Petersburg, Russia
  • Mg0004 40159
    Barcelona, Spain
  • Mg0004 40157
    L'Hospitalet de Llobregat, Spain
  • Mg0004 20080
    Taichung, Taiwan
  • Mg0004 20081
    Taipei, Taiwan
09

References and documents

Publications

  • Bril V, Druzdz A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vu T, Boehnlein M, Grimson F, Houston N, Kerbusch V, Pulido-Valdeolivas I, Tarancon T, Vissing J. Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions. Ther Adv Neurol Disord. 2026 Jun 29;19:17562864261458532. doi: 10.1177/17562864261458532. eCollection 2026. PubMed 42388397 ↗
  • Bril V, Druzdz A, Grosskreutz J, Habib AA, Kaminski HJ, Mantegazza R, Sacconi S, Utsugisawa K, Vu T, Boehnlein M, Gayfieva M, Greve B, Woltering F, Vissing J; MG0004 study investigators. Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. J Neurol. 2025 Mar 19;272(4):275. doi: 10.1007/s00415-025-12958-9. PubMed 40105996 ↗
  • Bril V, Druzdz A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. PubMed 37059507 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Sep 2021, 22 months.

Results were first posted in Aug 2023, 1 year 11 months after primary completion. A results delay was requested in Aug 2022.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 22 months is below that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2019
First posted
Oct 14, 2019
StartActual
Oct 29, 2019
Primary completionActual
Sep 1, 2021
CompletionActual
Sep 1, 2021
Results delay requested
Aug 31, 2022
Results first posted
Aug 21, 2023
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04124965
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Oct 14, 2019
Start date
Oct 29, 2019
Primary completion
Sep 1, 2021
Completion
Sep 1, 2021
Results posted
Aug 21, 2023
Last update
Aug 20, 2026

Study contacts

UCB Cares
study director · 001 844 599 22733 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion